← Back to Home

Active drug components detected in tumors from three glioblastoma patients, providing preliminary evidence of melflufen delivery

Surgically removed tumors offer direct clues to whether a drug can reach the disease site. Oncopeptides has released tissue analysis results from three patients, but this small study has yet to answer whether treatment can delay progression or extend life.

By SURL BioNews

Treating a brain tumor first requires getting the drug to the disease site. On October 9, Oncopeptides announced that researchers had detected active components in surgically removed tumor tissue from three glioblastoma patients who received melflufen. This provides early human evidence of drug delivery and brings the next question into sharper focus: once the drug reaches the tumor, can it produce an effect sufficient to improve the disease?

The open-label study, named INSULA and designated OP-701, is being conducted by Oslo University Hospital in Norway and enrolls patients scheduled for surgery because of recurrent glioblastoma. The study uses a “preoperative window” design, administering the drug before surgery and then analyzing the removed tissue to understand how the drug enters the tumor and its biological effects.

The company said active components were detected in the tumors of all three initial patients, at concentrations consistent with results from preclinical models; a same-day report by Nordic Life Science also documented this finding. Detection of active components in tumor tissue is the primary endpoint at this stage of the study. However, the announcement did not provide concentration values for individual patients or details of distribution within the tissue, so readers cannot yet use these findings to assess differences between patients.

Oncopeptides interprets the results as evidence supporting its peptide drug conjugate (PDC) platform’s ability to cross the blood-brain barrier. Based on the disclosed data, the more direct conclusion is that active components did reach the sampled tumor tissue; whether sufficient exposure can be achieved in other tumor regions, and whether this delivery can translate into a therapeutic effect, remain questions for further research.

Regarding tolerability, the company said no significant drug-related toxicity or unexpected surgical complications have been observed to date. The first patient has entered the extended treatment phase and has received a total of five monthly doses. The company announcement republished by News-Medical also reported that this patient had developed no new tumor-related neurological symptoms, while postoperative paresis attributed to surgery was improving. These observations come from very few patients and are not yet sufficient to characterize long-term safety.

INSULA continues to recruit, with a target of approximately ten patients, focusing on clarifying the drug’s absorption, distribution and biological effects, as well as whether patients can tolerate it. The study’s primary aim is not to evaluate progression-free survival or overall survival, so the current tissue findings and extended treatment records cannot be taken as proof that the drug extends life.

Next, these human tissue data will help the company plan further brain tumor studies and next-generation PDC drug candidates. Oncopeptides has also separately announced that it will hold an investor webcast on October 12 and make the presentation and recording publicly available afterward. The current advance provides clues that the drug reaches the disease site; more complete pharmacological, safety and efficacy evidence is still needed for it to become a treatment option.

References

  1. Oncopeptides
  2. Nordic Life Science
  3. Oncopeptides
  4. News-Medical (Oncopeptides release)